WCLC2022肺がんまとめ

概要

本スライドの対象者

参考文献

• WCLC2022

• A Multicenter Prospective Observational Study of Atezolizumab in Unresectable Advanced or Metastatic NSCLC in Japan: J-TAIL

• EGFR mutation is not a risk factor for postoperative recurrence of lung adenocarcinoma on long follow-up of a multi-institutional cohort

• Phase II Study of Durvalumab Plus Concurrent Radiotherapy in Unresectable Locally Advanced NSCLC: DOLPHIN Study (WJOG11619L)

• Liquid biopsy detects genomic drivers in non-small cell lung cancer without EGFR mutations by single-plex testing: WJOG13620L

• Clinico-genomic characteristics of patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations.